Calporta Therapeutics (Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- June 15, 2015
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $10,000,000
Company Info
- Company Description
- Calporta is developing selective small molecule agonists of TRPML1 for the treatment of Niemann-Pick C Disease (NPC) and other lysosomal storage diseases. Agonists of TRPML1 restore calcium efflux and normalize lysosomal trafficking and function.
- Market
- Lysosomal storage diseases
- Location
- La Jolla, California, USA
- Coinvestors
- Avalon Ventures, GlaxoSmithKline